Xiangnan Li
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 6
-
- Lung Cancer Diagnosis and Treatment 19
- Tracheal and airway disorders 11
- Pleural and Pulmonary Diseases 8
- Lung Cancer Treatments and Mutations 7
- Gastric Cancer Management and Outcomes 5
-
- Esophageal Cancer Research and Treatment 11
- Esophageal and GI Pathology 11
- Journals
- Scientific Reports (1 paper)Biochemical and Biophysical Research Communications (1 paper)CHEST Journal (1 paper)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Xiangnan Li
78 papers receiving 941 citations
Peers
Comparison fields: 5 of 102
- Cancer Research 215
- Pulmonary and Respiratory Medicine 309
- Oncology 187
- Molecular Biology 366
- Surgery 214
Countries citing papers authored by Xiangnan Li
This map shows the geographic impact of Xiangnan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiangnan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiangnan Li more than expected).
Fields of papers citing papers by Xiangnan Li
This network shows the impact of papers produced by Xiangnan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiangnan Li. The network helps show where Xiangnan Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xiangnan Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 1 | |
| 4 | 2025 | 2 | |
| 5 | 2025 | 0 | |
| 6 | 2024 | 0 | |
| 7 | 2024 | 1 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 2 | |
| 10 | 2022 | 4 | |
| 11 | 2022 | 26 | |
| 12 | 2022 | 1 | |
| 13 | Inhibition of CXCR4 ameliorates hypoxia-induced pulmonary arterial hypertension in rats. | 2021 | 12 |
| 14 | 2021 | 3 | |
| 15 | 2019 | 19 | |
| 16 | 2018 | 58 | |
| 17 | 2015 | 0 | |
| 18 | 2015 | 0 | |
| 19 | 2014 | 47 | |
| 20 | 2013 | 88 |
About Xiangnan Li
Xiangnan Li is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Surgery, having authored 85 papers that have together received 953 indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (19 papers), Esophageal Cancer Research and Treatment (11 papers), Tracheal and airway disorders (11 papers), Esophageal and GI Pathology (11 papers), Pleural and Pulmonary Diseases (8 papers), Lung Cancer Treatments and Mutations (7 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Gastric Cancer Management and Outcomes (5 papers). The work is most often cited by research in Cancer Research (215 citations), Pulmonary and Respiratory Medicine (309 citations) and Oncology (187 citations). Xiangnan Li has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Xue Pan, Minjie Shen, Dengyan Zhu, Dong Qiu, Hongbin Yuan, Donglei Liu, Kai Wu, Jia Zhao, Mei Yang and Yu Qi. Their work appears in journals such as Scientific Reports, Biochemical and Biophysical Research Communications and CHEST Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.